46
Participants
Start Date
September 6, 2019
Primary Completion Date
November 1, 2026
Study Completion Date
December 30, 2026
Niraparib
Niraparib is an oral PARP-1 and -2 inhibitor with high potency.
Trastuzumab
Trastuzumab is a commercially available agent administered by intravenous infusion. A loading dose of 8 mg/kg will be given as the first dose followed with all subsequent doses of 6 mg/kg every 3 weeks.
Montefiore, The Bronx
University of Pennsylvania, Philadelphia
University of North Carolina, Chapel Hill
University of Alabama at Birmingham, Birmingham
Mayo Clinic, Rochester
University of Chicago, Chicago
University of Washington-, Seattle
Translational Breast Cancer Research Consortium
OTHER
Tesaro, Inc.
INDUSTRY
Susan G. Komen Breast Cancer Foundation
OTHER
Breast Cancer Research Foundation of Alabama
UNKNOWN
The V Foundation
OTHER
University of Alabama at Birmingham
OTHER